Bert Lao
Senior Associate
Los Angeles
Practice Group
Regulatory
To realize your goals in the life sciences sector, an understanding of the regulatory intricacies of the U.S Food and Drug Administration (FDA) can be crucial. Bert Lao, a senior associate in our pharmaceutical and biotechnology practice, provides guidance to clients on a broad array of topics as they navigate one of the most heavily regulated industries in the United States.
Bert has counseled innovator pharmaceutical and biotechnology companies, investment groups, and contract research organizations on matters ranging from new drug approval to advertising and promotion compliance. With a background in biomedical engineering, Bert offers an interdisciplinary perspective on legal challenges that can become heavily intertwined with underlying scientific issues.
Industries
Areas of focus
Latest thinking and events
Publications
There'll be some changes made: President signs prescription drug and biologic user fee reauthorization act
Pharmaceutical Client AlertHogan Lovells Publications
Electric boogaloo: FDA releases sequel to 2003 guidance on use of electronic records and electronic signatures in clinical investigations
Publications
Just One More Day Compliance Deadline for New ClinicalTrials gov Regulations is Tuesday April 18 2017
Pharma/Biotech AlertHogan Lovells Publications
Much to Metabolize: The 21st Century Cures Act Introduces Numerous Changes to FDA’s Drug Regulatory Framework to Spur Development of New Treatments
Pharmaceutical and Biotechnology AlertHogan Lovells Publications
It’s Final: Expanded Registration and Results Submission Requirements for ClinicalTrials.gov
Pharmaceutical and Biotechnology AlertHogan Lovells Publications
FDA Issues Draft Guidance on Informed Consent Regulations
Focus on RegulationView More
